The DOI matches its Crossref record; 164 of the 164 references it cites were found in a registry or an index.
The Akt pathway in oncology therapy and beyond (Review)
Open accessAbstract
Protein kinase B (Akt), similar to many other protein kinases, is at the crossroads of cell death and survival, playing a pivotal role in multiple interconnected cell signaling mechanisms implicated in cell metabolism, growth and division, apoptosis suppression and angiogenesis. Akt protein kinase displays important metabolic effects, among which are glucose uptake in muscle and fat cells or the suppression of neuronal cell death. Disruptions in the Akt‑regulated pathways are associated with cancer, diabetes, cardiovascular and neurological diseases. The regulation of the Akt signaling pathway renders Akt a valuable therapeutic target. The discovery process of Akt inhibitors using various strategies has led to the identification of inhibitors with great selectivity, low side‑effects and toxicity. The usefulness of Akt emerges beyond cancer therapy and extends to other major diseases, such as diabetes, heart diseases, or neurodegeneration. This review presents key features of Akt structure and functions, and presents the progress of Akt inhibitors in regards to drug development, and their preclinical and clinical activity in regards to therapeutic efficacy and safety for patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
mTOR Signaling in Growth Control and Disease
Laplante, M., & Sabatini, D. M. (2012) · Cell · doi:10.1016/j.cell.2012.03.017 · Cited by 8,509
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
Cisplatin in cancer therapy: Molecular mechanisms of action
Dasari, S., & Bernard Tchounwou, P. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.025 · Cited by 5,537
Upstream and downstream of mTOR
Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181
TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling
Inoki, K., Li, Y., Zhu, T., Wu, J., & Guan, K.-L. (2002) · Nature Cell Biology · doi:10.1038/ncb839 · Cited by 3,083
Targeting the phosphoinositide 3-kinase pathway in cancer
Liu, P., Cheng, H., Roberts, T. M., & Zhao, J. J. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2926 · Cited by 2,721
Sakaguchi, S. (2005) · Nature Immunology · doi:10.1038/ni1178 · Cited by 2,669
PI3K/Akt signalling pathway and cancer
Vara, J. Á. F., Casado, E., de Castro, J., Cejas, P., Belda-Iniesta, C., & González-Barón, M. (2004) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2003.07.007 · Cited by 2,443
The activation of Akt/PKB signaling pathway and cell survival
Song, G., Ouyang, G., & Bao, S. (2005) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2005.tb00337.x · Cited by 1,888
Nagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.022 · Cited by 1,858 · cited 1×
“A low PTEN expression is a good predictor of poor responses to human epidermal growth factor receptor (HER2) antagonist therapies and it has been hypothesized that Akt inhibitors can overcome the development of resistance (57,58).”
Cho, H., Mu, J., Kim, J. K., Thorvaldsen, J. L., Chu, Q., Crenshaw, E. B., Kaestner, K. H., Bartolomei, M. S., Shulman, G. I., & Birnbaum, M. J. (2001) · Science · doi:10.1126/science.292.5522.1728 · Cited by 1,836
Goodnow, C. C., Crosbie, J., Adelstein, S., Lavoie, T. B., Smith-Gill, S. J., Brink, R. A., Pritchard-Briscoe, H., Wotherspoon, J. S., Loblay, R. H., Raphael, K., et al. (1988) · Nature · doi:10.1038/334676a0 · Cited by 1,565
Insulin Receptor Signaling in Normal and Insulin-Resistant States
Boucher, J., Kleinridders, A., & Kahn, C. R. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a009191 · Cited by 1,473
Perturbations of the AKT signaling pathway in human cancer
Altomare, D. A., & Testa, J. R. (2005) · Oncogene · doi:10.1038/sj.onc.1209085 · Cited by 1,329
PTEN and the PI3-Kinase Pathway in Cancer
Chalhoub, N., & Baker, S. J. (2009) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.4.110807.092311 · Cited by 1,245
Akt signalling in health and disease
Hers, I., Vincent, E. E., & Tavaré, J. M. (2011) · Cellular Signalling · doi:10.1016/j.cellsig.2011.05.004 · Cited by 1,239
Akt, FoxO and regulation of apoptosis
Zhang, X., Tang, N., Hadden, T. J., & Rishi, A. K. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.03.010 · Cited by 1,103
Role of Glutamate and NMDA Receptors in Alzheimer’s Disease
Wang, R., & Reddy, P. H. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160763 · Cited by 1,009
A Retroviral Oncogene, akt , Encoding a Serine-Threonine Kinase Containing an SH2-Like Region
Bellacosa, A., Testa, J. R., Staal, S. P., & Tsichlis, P. N. (1991) · Science · doi:10.1126/science.1833819 · Cited by 939
Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer
Nahta, R., Yu, D., Hung, M.-C., Hortobagyi, G. N., & Esteva, F. J. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0509 · Cited by 916
Bibbins-Domingo, K., & on behalf of the U.S. Preventive Services Task Force* (2016) · Annals of Internal Medicine · doi:10.7326/m16-0577 · Cited by 854
Molecular alterations of the AKT 2 oncogene in ovarian and breast carcinomas
Bellacosa, A., De Feo, D., Godwin, A. K., Bell, D. W., Cheng, J. Q., Altomare, D. A., Wan, M., Dubeau, L., Scambia, G., Masciullo, V., et al. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910640412 · Cited by 837
Advances in protein kinase B signalling: AKTion on multiple fronts
Brazil, D. P., Yang, Z.-Z., & Hemmings, B. A. (2004) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2004.03.006 · Cited by 830
Activation of AKT Kinases in Cancer: Implications for Therapeutic Targeting
(2005) · Advances in Cancer Research · doi:10.1016/s0065-230x(05)94002-5 · Cited by 823
The PI3K/AKT Pathway as a Target for Cancer Treatment
Mayer, I. A., & Arteaga, C. L. (2016) · Annual Review of Medicine · doi:10.1146/annurev-med-062913-051343 · Cited by 822
PDK1, the master regulator of AGC kinase signal transduction
Mora, A., Komander, D., van Aalten, D. M. F., & Alessi, D. R. (2004) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2003.12.022 · Cited by 810
Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis
Dorlo, T. P. C., Balasegaram, M., Beijnen, J. H., & de Vries, P. J. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks275 · Cited by 775
mTORC1-Mediated Cell Proliferation, But Not Cell Growth, Controlled by the 4E-BPs
Dowling, R. J. O., Topisirovic, I., Alain, T., Bidinosti, M., Fonseca, B. D., Petroulakis, E., Wang, X., Larsson, O., Selvaraj, A., Liu, Y., et al. (2010) · Science · doi:10.1126/science.1187532 · Cited by 726
Seca, A., & Pinto, D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19010263 · Cited by 686
The molecular mechanisms of chemoresistance in cancers
Zheng, H.-C. (2017) · Oncotarget · doi:10.18632/oncotarget.19048 · Cited by 624
Brognard, J., Sierecki, E., Gao, T., & Newton, A. C. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.02.017 · Cited by 591
The multiple pathways to autoimmunity
Theofilopoulos, A. N., Kono, D. H., & Baccala, R. (2017) · Nature Immunology · doi:10.1038/ni.3731 · Cited by 590
Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks
Pommier, Y., Sordet, O., Antony, S., Hayward, R. L., & Kohn, K. W. (2004) · Oncogene · doi:10.1038/sj.onc.1207515 · Cited by 560
Yap, T. A., Yan, L., Patnaik, A., Fearen, I., Olmos, D., Papadopoulos, K., Baird, R. D., Delgado, L., Taylor, A., Lupinacci, L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.5263 · Cited by 539
Molecular Mechanisms of Glutamate Receptor-Mediated Excitotoxic Neuronal Cell Death
Sattler, R., & Tymianski, M. (2001) · Molecular Neurobiology · doi:10.1385/mn:24:1-3:107 · Cited by 537
Jones, P. F., Jakubowicz, T., Pitossi, F. J., Maurer, F., & Hemmings, B. A. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.10.4171 · Cited by 532
Aoki, H., Takada, Y., Kondo, S., Sawaya, R., Aggarwal, B. B., & Kondo, Y. (2007) · Molecular Pharmacology · doi:10.1124/mol.106.033167 · Cited by 523
Impaired Fas Response and Autoimmunity in Pten +/− Mice
Cristofano, A. D., Kotsi, P., Peng, Y. F., Cordon-Cardo, C., Elkon, K. B., & Pandolfi, P. P. (1999) · Science · doi:10.1126/science.285.5436.2122 · Cited by 521
COFFER, P. J., & WOODGETT, J. R. (1991) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1991.tb16305.x · Cited by 487
PTEN Tumor Suppressor Network in PI3K-Akt Pathway Control
Georgescu, M.-M. (2010) · Genes & Cancer · doi:10.1177/1947601911407325 · Cited by 482
Nakatani, K., Thompson, D. A., Barthel, A., Sakaue, H., Liu, W., Weigel, R. J., & Roth, R. A. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.31.21528 · Cited by 475
Davies, B. R., Greenwood, H., Dudley, P., Crafter, C., Yu, D.-H., Zhang, J., Li, J., Gao, B., Ji, Q., Maynard, J., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0824-t · Cited by 471
PTEN: Multiple Functions in Human Malignant Tumors
Milella, M., Falcone, I., Conciatori, F., Cesta Incani, U., Del Curatolo, A., Inzerilli, N., Nuzzo, C. M. A., Vaccaro, V., Vari, S., Cognetti, F., et al. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00024 · Cited by 463
PI3K/Akt/mTOR signaling pathway in cancer stem cells: from basic research to clinical application.
Pu, X., & Xu, X. (2015) · Europe PMC (PubMed Central) · Cited by 453
Mhyre, T. R., Boyd, J. T., Hamill, R. W., & Maguire-Zeiss, K. A. (2012) · Subcellular Biochemistry · doi:10.1007/978-94-007-5416-4_16 · Cited by 423
McMullen, J. R., Boey, E. J. H., Ooi, J. Y. Y., Seymour, J. F., Keating, M. J., & Tam, C. S. (2014) · Blood · doi:10.1182/blood-2014-10-604272 · Cited by 403
Unravelling the activation mechanisms of protein kinase B/Akt
Scheid, M. P., & Woodgett, J. R. (2003) · FEBS Letters · doi:10.1016/s0014-5793(03)00562-3 · Cited by 390
The life of a cell: apoptosis regulation by the PI3K/PKB pathway
Duronio, V. (2008) · Biochemical Journal · doi:10.1042/bj20081056 · Cited by 390
Akt-dependent and -independent mechanisms of mTOR regulation in cancer
Memmott, R. M., & Dennis, P. A. (2009) · Cellular Signalling · doi:10.1016/j.cellsig.2009.01.004 · Cited by 382
Tamura, M., Gu, J., Danen, E. H. J., Takino, T., Miyamoto, S., & Yamada, K. M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.29.20693 · Cited by 376
Yang, L., Dan, H. C., Sun, M., Liu, Q., Sun, X.-M., Feldman, R. I., Hamilton, A. D., Polokoff, M., Nicosia, S. V., Herlyn, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0343 · Cited by 371
Jo, H., Mondal, S., Tan, D., Nagata, E., Takizawa, S., Sharma, A. K., Hou, Q., Shanmugasundaram, K., Prasad, A., Tung, J. K., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1202810109 · Cited by 367
Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review)
NITULESCU, G. M., MARGINA, D., JUZENAS, P., PENG, Q., OLARU, O. T., SALOUSTROS, E., FENGA, C., SPANDIDOS, D. A., LIBRA, M., & TSATSAKIS, A. M. (2016) · International Journal of Oncology · doi:10.3892/ijo.2015.3306 · Cited by 364
Self-citationGSK3 and tau: Two convergence points in Alzheimer’s disease
Hernandez, F., Lucas, J. J., & Avila, J. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-129025 · Cited by 359
Sato, K., Tsuchihara, K., Fujii, S., Sugiyama, M., Goya, T., Atomi, Y., Ueno, T., Ochiai, A., & Esumi, H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1462 · Cited by 352
Fernandez, D., Bonilla, E., Mirza, N., Niland, B., & Perl, A. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22085 · Cited by 319
Haddadi, N., Lin, Y., Travis, G., Simpson, A. M., Nassif, N. T., & McGowan, E. M. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0803-3 · Cited by 312
Insulin action on glucose transporters through molecular switches, tracks and tethers
Zaid, H., Antonescu, C. N., Randhawa, V. K., & Klip, A. (2008) · Biochemical Journal · doi:10.1042/bj20080723 · Cited by 286
AKT in cancer: new molecular insights and advances in drug development
Mundi, P. S., Sachdev, J., McCourt, C., & Kalinsky, K. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13021 · Cited by 272
Current evidence on the effect of dietary polyphenols intake on chronic diseases
Costa, C., Tsatsakis, A., Mamoulakis, C., Teodoro, M., Briguglio, G., Caruso, E., Tsoukalas, D., Margina, D., Dardiotis, E., Kouretas, D., et al. (2017) · Food and Chemical Toxicology · doi:10.1016/j.fct.2017.10.023 · Cited by 258
Self-citationAkt as a mediator of cell death
Luo, H. R., Hattori, H., Hossain, M. A., Hester, L., Huang, Y., Lee-Kwon, W., Donowitz, M., Nagata, E., & Snyder, S. H. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1634990100 · Cited by 248
Akt inhibitors in clinical development for the treatment of cancer
Pal, S. K., Reckamp, K., Yu, H., & Figlin, R. A. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.520701 · Cited by 226
The FOXO3-FOXM1 axis: A key cancer drug target and a modulator of cancer drug resistance
Yao, S., Fan, L. Y.-N., & Lam, E. W.-F. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.11.018 · Cited by 223
Goodnow, C. C., Crosbie, J., Adelstein, S., Lavoie, T., Smith‐Gill, S. J., Brink, R. A., Pritchard-Briscoe, H., Wotherspoon, J. S., Loblay, R. H., Raphael, K., et al. (2009) · PubMed · Cited by 221
Maximising the potential of AKT inhibitors as anti-cancer treatments
Brown, J. S., & Banerji, U. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.12.001 · Cited by 221
Regulatory T cell proliferative potential is impaired in human autoimmune disease
Carbone, F., De Rosa, V., Carrieri, P. B., Montella, S., Bruzzese, D., Porcellini, A., Procaccini, C., La Cava, A., & Matarese, G. (2014) · Nature Medicine · doi:10.1038/nm.3411 · Cited by 211
PIKKing on PKB: regulation of PKB activity by phosphorylation
Bozulic, L., & Hemmings, B. A. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2009.02.002 · Cited by 208
The interplay between inflammation and metabolism in rheumatoid arthritis
Chimenti, M. S., Triggianese, P., Conigliaro, P., Candi, E., Melino, G., & Perricone, R. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.246 · Cited by 207
Ahmad, A., Biersack, B., Li, Y., Kong, D., Bao, B., Schobert, R., Padhye, S., & Sarkar, F. (2013) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/18715206113139990078 · Cited by 200
The Importance of the PI3K/AKT/MTOR Pathway in the Progression of Ovarian Cancer
Dobbin, Z., & Landen, C. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms14048213 · Cited by 191
The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug.
Juárez, M., Schcolnik‐Cabrera, A., & Dueñas‐González, A. (2018) · PubMed · Cited by 189
Dai, B., Wu, Q., Zeng, C., Zhang, J., Cao, L., Xiao, Z., & Yang, M. (2016) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2016.07.024 · Cited by 188
Pretorius, L., Du, X.-J., Woodcock, E. A., Kiriazis, H., Lin, R. C. Y., Marasco, S., Medcalf, R. L., Ming, Z., Head, G. A., Tan, J. W., et al. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.090126 · Cited by 187
The Role of the Mammalian Target of Rapamycin (mTOR) in Pulmonary Fibrosis
Lawrence, J., & Nho, R. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030778 · Cited by 183
Warner, L. M., Adams, L. M., & Sehgal, S. N. (1994) · Arthritis & Rheumatism · doi:10.1002/art.1780370219 · Cited by 180
An Activating Mutation of AKT2 and Human Hypoglycemia
Hussain, K., Challis, B., Rocha, N., Payne, F., Minic, M., Thompson, A., Daly, A., Scott, C., Harris, J., Smillie, B. J. L., et al. (2011) · Science · doi:10.1126/science.1210878 · Cited by 178
Saura, C., Roda, D., Roselló, S., Oliveira, M., Macarulla, T., Pérez-Fidalgo, J. A., Morales-Barrera, R., Sanchis-García, J. M., Musib, L., Budha, N., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0512 · Cited by 172
Kobayashi, M., & Zochodne, D. W. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12833 · Cited by 171
Targeting the AKT protein kinase for cancer chemoprevention
Crowell, J. A., Steele, V. E., & Fay, J. R. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0120 · Cited by 170
Group I Metabotropic Glutamate Receptor Signalling and its Implication in Neurological Disease
Ribeiro, F. M., Paquet, M., Cregan, S. P., & Ferguson, S. S. G. (2010) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152710793361612 · Cited by 159
Lai, Z., Borsuk, R., Shadakshari, A., Yu, J., Dawood, M., Garcia, R., Francis, L., Tily, H., Bartos, Á., Faraone, S. V., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1301005 · Cited by 158
Flavones inhibit breast cancer proliferation through the Akt/FOXO3a signaling pathway
Lin, C.-H., Chang, C.-Y., Lee, K., Lin, H.-J., Chen, T.-H., & Wan, L. (2015) · BMC Cancer · doi:10.1186/s12885-015-1965-7 · Cited by 157
Banerji, U., Dean, E. J., Fidalgo, J. A. P., Batist, G., Bedard, P. L., You, B., Westin, S. N., Kabos, P., Garrett, M. D., Tall, M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2260 · Cited by 154
Dumble, M. L., Crouthamel, M., Zhang, S., Schaber, M. D., Levy, D. S., Robell, K. A., Liu, Q., Figueroa, D. J., Minthorn, E. A., Seefeld, M. A., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100880 · Cited by 151
The Opposing Actions of Target of Rapamycin and AMP-Activated Protein Kinase in Cell Growth ControlPreprint
Hindupur, S. K., González, A., & Hall, M. N. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a019141 · Cited by 150
Akt as a target for cancer therapy: more is not always better (lessons from studies in mice)
Wang, Q., Chen, X., & Hay, N. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.153 · Cited by 149
Reddy, P. H. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.06.012 · Cited by 147
Pathologic Caveolin-1 Regulation of PTEN in Idiopathic Pulmonary Fibrosis
Hong, X., Khalil, W., Kahm, J., Jessurun, J., Kleidon, J., & Henke, C. A. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.091117 · Cited by 146
Zhou, R., Chen, H., Chen, J., Chen, X., Wen, Y., & Xu, L. (2018) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-018-2148-2 · Cited by 146
Spencer, A., Yoon, S.-S., Harrison, S. J., Morris, S. R., Smith, D. A., Brigandi, R. A., Gauvin, J., Kumar, R., Opalinska, J. B., & Chen, C. (2014) · Blood · doi:10.1182/blood-2014-03-559963 · Cited by 142
Lycopene inhibits growth of human colon cancer cells via suppression of the Akt signaling pathway
Tang, F., Shih, C.-J., Cheng, L., Ho, H., & Chen, H. C. (2008) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200700272 · Cited by 142
Lu, Y., Azad, N., Wang, L., Iyer, A. K. V., Castranova, V., Jiang, B.-H., & Rojanasakul, Y. (2010) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2009-0002oc · Cited by 138
Pathogenic autoantibodies in lupus nephritis
Waldman, M. T. G., & Madaio, M. P. (2005) · Lupus · doi:10.1191/0961203305lu2054oa · Cited by 138
Turning Off AKT: PHLPP as a Drug Target
Newton, A. C., & Trotman, L. C. (2014) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011112-140338 · Cited by 136
The PI3K/Akt pathway: a critical player in intervertebral disc degeneration
Ouyang, Z., Wang, W.-J., Yan, Y., Wang, B., & Lv, G. (2017) · Oncotarget · doi:10.18632/oncotarget.18628 · Cited by 134
Lipophilic statins limit cancer cell growth and survival, via involvement of Akt signaling
Beckwitt, C. H., Shiraha, K., & Wells, A. H. (2018) · PLoS ONE · doi:10.1371/journal.pone.0197422 · Cited by 122
Zhang, H., Wang, Y., Xie, J. F., Liang, X., Liu, D., Yang, P., Hsu, H., Ray, R. B., & Mountz, J. D. (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200107)44:7<1555::aid-art279>3.0.co;2-m · Cited by 120
Tubastatin ameliorates pulmonary fibrosis by targeting the TGFβ-PI3K-Akt pathway
Saito, S., Zhuang, Y., Shan, B., Danchuk, S. D., Luo, F., Korfei, M., Günther, A., & Lasky, J. A. (2017) · PLoS ONE · doi:10.1371/journal.pone.0186615 · Cited by 119
Wong, F. C., Woo, C. C., Hsu, A., & Tan, B. K. H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078021 · Cited by 115
Conus, N. M., Hannan, K. M., Cristiano, B. E., Hemmings, B. A., & Pearson, R. B. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203387200 · Cited by 114
Akt isoforms in vascular disease
Yu, H., Littlewood, T. D., & Bennett, M. R. (2015) · Vascular Pharmacology · doi:10.1016/j.vph.2015.03.003 · Cited by 114
Regulation of PI3K effector signalling in cancer by the phosphoinositide phosphatases
Rodgers, S. J., Ferguson, D. T., Mitchell, C. A., & Ooms, L. M. (2017) · Bioscience Reports · doi:10.1042/bsr20160432 · Cited by 110
Hu, M. C., Li, F., & Wang, W. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s156920 · Cited by 108
Richardson, P. G. G., Eng, C., Kolesar, J., Hideshima, T., & Anderson, K. C. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.681376 · Cited by 101
The Role of Mechanistic Target of Rapamycin (mTOR) Complexes Signaling in the Immune Responses
Soliman, G. A. (2013) · Nutrients · doi:10.3390/nu5062231 · Cited by 97
Cristiano, B. E., Chan, J. C., Hannan, K. M., Lundie, N. A., Marmy-Conus, N., Campbell, I., Phillips, W. A., Robbie, M. J., Hannan, R. D., & Pearson, R. B. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1968 · Cited by 95
The AKT/mTOR signaling pathway plays a key role in statin-induced myotoxicity
Bonifacio, A., Sanvee, G. M., Bouitbir, J., & Krähenbühl, S. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.04.010 · Cited by 94
Berndt, N., Yang, H., Trinczek, B., Betzi, S., Zhang, Z., Wu, B., Lawrence, N. J., Pellecchia, M., Schönbrunn, E., Cheng, J. Q., et al. (2010) · Cell Death & Differentiation · doi:10.1038/cdd.2010.63 · Cited by 93
Ganetespib: research and clinical development
Modi, S., & Jhaveri, K. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s65804 · Cited by 92
Lim, C.-Y., Bi, X., Wu, D., Kim, J. B., Gunning, P. W., Hong, W., & Han, W. (2015) · Nature Communications · doi:10.1038/ncomms6951 · Cited by 88
The critical molecular interconnections in regulating apoptosis and autophagy
Zhao, G., Pan, H., Ouyang, D.-Y., & He, X. (2015) · Annals of Medicine · doi:10.3109/07853890.2015.1040831 · Cited by 87
Nho, R. S., Hergert, P. J., Kahm, J., Jessurun, J., & Henke, C. A. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.07.020 · Cited by 87
Gao, S., Guo, Q. H., Qin, C., Shang, R., & Zhang, Z. (2017) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.6b04682 · Cited by 85
Ranieri, C., Tommaso, S. D., Loconte, D. C., Grossi, V., Sanese, P., Bagnulo, R., Susca, F. C., Forte, G., Peserico, A., Luisi, A. D., et al. (2018) · Neurogenetics · doi:10.1007/s10048-018-0540-1 · Cited by 85
Lü, Q., Zuo, W.-Z., Ji, X., Zhou, Y., Liu, Y., Yao, X., Zhou, X., Liu, Y., Zhang, F., & Yin, X. (2015) · Phytomedicine · doi:10.1016/j.phymed.2015.08.010 · Cited by 84
Nho, R. S., Peterson, M., Hergert, P. J., & Henke, C. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061017 · Cited by 83
Group I metabotropic glutamate receptors reduce excitotoxic injury and may facilitate neurogenesis
Baskys, A., Bayazitov, I. T., Fang, L., Blaabjerg, M., Poulsen, F. R., & Zimmer, J. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.04.029 · Cited by 83
Sierecki, E., Sinko, W., McCammon, J. A., & Newton, A. C. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100331d · Cited by 82
Estrada, A. C., Syrovets, T., Pitterle, K., Lunov, O., Büchele, B., Schimana-Pfeifer, J., Schmidt, T. J., Morad, S. A. F., & Simmet, T. (2009) · Molecular Pharmacology · doi:10.1124/mol.109.060475 · Cited by 80
Alkylphospholipids: An update on molecular mechanisms and clinical relevance
Ríos‐Marco, P., Marco, C., Gálvez, X., Jiménez‐López, J. M., & Carrasco, M. P. (2017) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2017.02.016 · Cited by 78
PTEN Inhibition in Human Disease Therapy
Pulido, R. (2018) · Molecules · doi:10.3390/molecules23020285 · Cited by 77
Li, X., Lu, F., Tian, Q., Yang, Y., Wang, Q., & Wang, J. (2005) · Journal of Neural Transmission · doi:10.1007/s00702-005-0303-7 · Cited by 71
Natural products—friends or foes?
Margina, D. M., Ilie, M., Grădinaru, D., Androutsopoulos, V. P., Kouretas, D., & Tsatsakis, A. M. (2015) · Toxicology Letters · doi:10.1016/j.toxlet.2015.05.009 · Cited by 70
Self-citationRepression of AKT signaling by ARQ 092 in cells and tissues from patients with Proteus syndrome
Lindhurst, M. J., Yourick, M. R., Yu, Y., Savage, R. E., Ferrari, D., & Biesecker, L. G. (2015) · Scientific Reports · doi:10.1038/srep17162 · Cited by 67
Autophagy: novel applications of nonsteroidal anti‐inflammatory drugs for primary cancer
Chen, Y., Li, W., Liu, J., Lu, J., & Feng, J. (2017) · Cancer Medicine · doi:10.1002/cam4.1287 · Cited by 64
Mattmann, M. E., Stoops, S. L., & Lindsley, C. W. (2011) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2011.587959 · Cited by 63
The AKT Axis as a Therapeutic Target in Autoimmune Diseases
Wu, T., & Mohan, C. (2009) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/187153009788452417 · Cited by 62
Lim, W., Yang, C., Bazer, F. W., & Song, G. (2016) · Biology of Reproduction · doi:10.1095/biolreprod.116.141556 · Cited by 61
Politz, O., Siegel, F., Bärfacker, L., Bömer, U., Hägebarth, A., Scott, W. J., Michels, M., Ince, S. J., Neuhaus, R., Meyer, K., et al. (2016) · International Journal of Cancer · doi:10.1002/ijc.30457 · Cited by 61
Gunadharini, D. N., Perumal, E., Arunkumar, R., Senthilkumar, K., & Arunakaran, J. (2011) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2011.01.015 · Cited by 60
Different effects of statins on induction of diabetes mellitus: an experimental study
Zhao, S., & Wang, Z. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s87979 · Cited by 60
Aghajanian, C. A., Bell‐McGuinn, K. M., Burris, H. A., Siu, L. L., Stayner, L.-A., Wheler, J. J., Hong, D. S., Kurkjian, C. D., Pant, S., Santiago-Walker, A., et al. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0591-z · Cited by 58
Phase I study of tricyclic nucleoside phosphate using a five-day continuous infusion schedule.
Feun, L. G., Savaraj, N., Bodey, G. P., Lu, K., Yap, B. S., Ajani, J. A., Burgess, M. A., Benjamin, R. S., McKelvey, E. M., & Krakoff, I. H. (1984) · PubMed · Cited by 55
Ying, C., Mao, Y., Chen, L., Wang, S., Ling, H., Li, W., & Zhou, X. (2017) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2017.03.124 · Cited by 55
Yang, L., Liu, Y., Wang, M., Qian, Y., Dai, X., Zhu, Y., Chen, J., Guo, S., & Hisamitsu, T. (2016) · Oncology Letters · doi:10.3892/ol.2016.5213 · Cited by 49
Montaño, A., Forero‐Castro, M., Marchena-Mendoza, D., Benito, R., & Hernández‐Rivas, J. M. (2018) · Cancers · doi:10.3390/cancers10040110 · Cited by 48
Lin, Y.-H., Chen, B. Y.-H., Lai, W.-T., Wu, S.-F., Guh, J., Cheng, A., & Hsu, L. (2014) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-014-1032-y · Cited by 47
Jin, J., Jin, L. G., Lim, S. W., & Yang, C. W. (2016) · American Journal of Nephrology · doi:10.1159/000446447 · Cited by 42
Akt inhibitor MK-2206 enhances the effect of cisplatin in gastric cancer cells
Tao, K., Yin, Y., Shen, Q., Chen, Y., Li, R., Chang, W., Bai, J., Liu, W., Shi, L., & Zhang, P. (2016) · Biomedical Reports · doi:10.3892/br.2016.594 · Cited by 40
Recent progress towards clinically relevant ATP-competitive Akt inhibitors
Huck, B. R., & Mochalkin, I. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.04.090 · Cited by 40
Hematopoietic Akt2 deficiency attenuates the progression of atherosclerosis
Rotllán, N., Chamorro-Jorganes, A., Araldi, E., Wanschel, A. C. B. A., Aryal, B. K., Aranda, J. F., Goedeke, L., Salerno, A. G., Ramírez, C. M., Sessa, W. C., et al. (2014) · The FASEB Journal · doi:10.1096/fj.14-262097 · Cited by 39
Anticancer potential of selected Fallopia Adans species
Olaru, O. T., Venables, L., van de Venter, M., Nițulescu, G. M., Margina, D. M., Spandidos, D. A., & Tsatsakis, A. M. (2015) · Oncology Letters · doi:10.3892/ol.2015.3453 · Cited by 39
Self-citationChen, Z., Chen, B., Xu, W., Liu, R., Yang, J., & Yu, C. (2012) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2012.08.003 · Cited by 38
Geuna, E., Roda, D., Rafii, S., Jiménez, B., Capelán, M., Rihawi, K., Montemurro, F., Yap, T. A., Kaye, S. B., Bono, J. S. D., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.373 · Cited by 35
Itraconazole Inhibits AKT/mTOR Signaling and Proliferation in Endometrial Cancer Cells
Tsubamoto, H., Inoue, K., Sakata, K., Ueda, T., Takeyama, R., Shibahara, H., & SONODA, T. (2017) · Anticancer Research · doi:10.21873/anticanres.11343 · Cited by 35
SC79 protects dopaminergic neurons from oxidative stress
Xu, Y., Gao, Y., & Yang, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.23538 · Cited by 35
Protein Kinases as Drug Development Targets for Heart Disease Therapy
Dhalla, N. S., & Muller, A. L. (2010) · Pharmaceuticals · doi:10.3390/ph3072111 · Cited by 34
Kim, K., Li, J., Barazia, A., Tseng, A., Youn, S., Abbadessa, G., Yu, Y., Schwartz, B. E., Andrews, R. K., Gordeuk, V. R., et al. (2016) · Haematologica · doi:10.3324/haematol.2016.151159 · Cited by 32
Guerra, A. C. V. D. A., Soares, L. A. L., Ferreira, M. R. A., de Araújo, A. A., Rocha, H. A. O., de Medeiros, J. S., Cavalcante, R. S., & Júnior, R. F. D. A. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.05.123 · Cited by 30
Li, Q., Ni, W., Deng, Z., Liu, M., She, L., & Xie, Q. (2017) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12266 · Cited by 29
Sulfuretin Attenuates MPP+-Induced Neurotoxicity through Akt/GSK3β and ERK Signaling Pathways
Pariyar, R., Lamichhane, R., Jung, H., Kim, S. H., & Seo, J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122753 · Cited by 27
The role of mouse Akt2 in insulin-dependent suppression of adipocyte lipolysis in vivo
Koren, S., DiPilato, L. M., Emmett, M. J., Shearin, A. L., Chu, Q., Monks, B. R., & Birnbaum, M. J. (2015) · Diabetologia · doi:10.1007/s00125-015-3532-9 · Cited by 26
Insulin-Leptin Axis, Cardiometabolic Risk and Oxidative Stress in Elderly with Metabolic Syndrome
Grădinaru, D., Khaddour, H., Margina, D. M., Ungurianu, A., Borșa, C., Ionescu, C., Prada, G. I., Usher, J. L., & Elshimali, Y. (2018) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0043-123825 · Cited by 26
Self-citationCarpi, S., Polini, B., Poli, G., Barata, G. A., Fogli, S., Romanini, A., Tuccinardi, T., Guella, G., Frontini, F. P., Nieri, P., et al. (2018) · Marine Drugs · doi:10.3390/md16050166 · Cited by 26
Arceci, R. J., Allen, C. E., Dunkel, I. J., Jacobsen, E. D., Whitlock, J. A., Vassallo, R., Morris, S. R., Portnoy, A., Reedy, B. A., Smith, D. A., et al. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.26325 · Cited by 24
Han, H.-Y., Kim, H. J., Jeong, S.-H., Kim, J., Jeong, S., Kim, G., Hwang, D., Kim, U., & Ryu, M. H. (2018) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2018/5765047 · Cited by 24
Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer
Sundar, R., Chénard-Poirier, M., Collins, D. C., & Yap, T. A. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00039 · Cited by 22
Necessity to evaluate PI3K/Akt signalling pathway in proarrhythmia
Ezeani, M., & Elom, S. O. (2017) · Open Heart · doi:10.1136/openhrt-2017-000596 · Cited by 22
Bjune, K., Sundvold, H., Leren, T. P., & Naderi, S. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.07.009 · Cited by 22
Targeting PTEN interactions for Alzheimer's disease
Frère, S. G. A., & Slutsky, I. (2016) · Nature Neuroscience · doi:10.1038/nn.4248 · Cited by 15
Tan, Z., Peng, A., Xu, J., & Ouyang, M.-W. (2017) · BMC Anesthesiology · doi:10.1186/s12871-017-0423-2 · Cited by 15
Pan, Y., Wang, W.-H., Huang, T.-Y., Weng, W.-H., Fang, C.-K., Chen, Y.-C., & Hwang, J. (2018) · Inflammation Research · doi:10.1007/s00011-018-1176-1 · Cited by 13
PTEN contributes to Alzheimer’s disease
Ferrarelli, L. K. (2016) · Science Signaling · doi:10.1126/scisignal.aaf5520 · Cited by 3
(2010) · PubMed Central
Cited by
The anti-cancer effect of quercetin: molecular implications in cancer metabolism
Reyes-Farias, M., & Carrasco-Pozo, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133177 · Cited by 689
“AMPK controls glucose and lipid metabolism by sensing changes in nutrient and extracellular energy levels [26].”
BackgroundAdvancements in clinical aspects of targeted therapy and immunotherapy in breast cancer
Ye, F., Dewanjee, S., Li, Y., Jha, N. K., Chen, Z.-S., Kumar, A., Vishakha, Behl, T., Jha, S. K., & Tang, H. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01805-y · Cited by 554
The interplay between androgens and the immune response in polycystic ovary syndrome
Shabbir, S., Khurram, E., Moorthi, V. S., Eissa, Y. T. H., Kamal, M. A., & Butler, A. E. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04116-4 · Cited by 108
New drugs are not enough‑drug repositioning in oncology: An update
Armando, R., Mengual G�mez, D., & Gomez, D. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.4966 · Cited by 90
Mitochondria: The metabolic switch of cellular oncogenic transformation
Tan, Y. Q., Zhang, X., Zhang, S., Zhu, T., Garg, M., Lobie, P. E., & Pandey, V. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188534 · Cited by 75
Metadata
- Authors
- Nitulescu, G., Van De Venter, M., Nitulescu, G., Ungurianu, A., Juzenas, P., Peng, Q., Olaru, O., Grădinaru, D., Tsatsakis, A., Tsoukalas, D., Spandidos, D., & Margina, D.
- Venue
- International Journal of Oncology
- Publisher
- Spandidos Publications
- Published
- 2018-10-16
- Volume
- 53
- Issue
- 6
- Pages
- 2319-2331
- ISSN
- 1019-6439 (ISSN-L)
- 1791-2423
- OpenAlex
- W2896744886
- Cited by
- 328
- References
- 164
- FWCI
- 10.04
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.